|Table of Contents|

Expression and clinical significance of GNPNAT1 and HDAC11 in non-small cell lung cancer tissues

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2024 21
Page:
4089-4095
Research Field:
Publishing date:

Info

Title:
Expression and clinical significance of GNPNAT1 and HDAC11 in non-small cell lung cancer tissues
Author(s):
SHEN Jie1; 2; ZHANG Jie2
1.Department of Clinical Laboratory,Hai'an People's Hospital,Jiangsu Hai'an 226600,China;2.Department of Immunology,Nantong University Medical College,Jiangsu Nantong 226019,China.
Keywords:
non-small cell lung cancer(NSCLC); glucosamine-phosphate N-acetyltransferase 1(GNPNAT1); histone deacetylases 11(HDAC11); immunohistochemistry; prognostic biomarker
PACS:
R734.2
DOI:
10.3969/j.issn.1672-4992.2024.21.013
Abstract:
Objective:To investigate the expression of glucosamine-phosphate N-acetyltransferase 1(GNPNAT1) and histone deacetylases 11(HDAC11) and their clinical significance in non-small cell lung cancer(NSCLC).Methods:Immunohistochemistry(IHC) staining was used to detect the expression of GNPNAT1 and HDAC11 proteins in 158 surgically resected NSCLC tissues and adjacent normal tissues.The relationships between the expression of the two proteins and tumor histopathological characteristics were analyzed,and the overall survival(OS) rates of NSCLC patients with high and low expression of GNPNAT1 and HDAC11 were calculated by Kaplan-Meier methods.The univariate and multivariate Cox regression analysis were conducted to determine independent prognostic factors for NSCLC patients.Results:The expression of GNPNAT1(Z=8.611,P＜0.001) and HDAC11 protein(Z=7.731,P＜0.001) were higher in NSCLC tissues than in adjacent normal tissues.According to the results of IHC staining,high expression of GNPNAT1 protein was observed in 80 cases(50.6%) and high expression of HDAC11 protein was detected in 75 cases(47.5%) of 158 NSCLC samples.The proportions of moderate/poor differentiation(χ２=33.747,P＜0.001) and TNM stage Ⅱ-Ⅲ(χ２=13.664,P=0.001) were higher,and lymph node metastasis(χ２=10.534,P=0.001) and lymphovascular invasion(χ２=5.425,P=0.020) were more frequent in patients with high expression of GNPNAT1.On the other hand,high expression of HDAC11 was significantly correlated with lymph node metastasis(χ２=8.265,P=0.004),perineural invasion(χ２=4.373,P=0.037) and TNM stage(χ２=6.472,P=0.039).The 3-year OS rates of patients with high and low GNPNAT1 expression were 67.5% and 88.3%,respectively(χ２=16.362,P＜0.001).The 3-year OS rates of patients with high and low HDAC11 expression were 61.4% and 91.3%,respectively(χ２=8.864,P=0.003).Univariate and multivariate Cox regression analysis demonstrated that high expression of GNPNAT1(P=0.014,HR:2.236,95%CI:1.180~4.239) and HDAC11(P=0.042,HR:1.813,95%CI:1.022~3.218) were independent prognostic factors for NSCLC patients.Conclusion:High expression of GNPNAT1 and HDAC11 were associated with tumor invasive features and poor prognosis,and they might be valuable prognostic biomarkers for NSCLC patients.

References:

［1］BRAY F,LAVERSANNE M,SUNG H,et al.Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin,2024，74（3）：229-263.
［2］SIEGEL RL,GIAQUINTO AN,JEMAL A.Cancer statistics,2024［J］.CA Cancer J Clin,2024,74(1):12-49.
［3］KRATZER TB,BANDI P,FREEDMAN ND,et al.Lung cancer statistics,2023［J］.Cancer,2024,130(8):1330-1348.
［4］KIM F,BORGEAUD M,ADDEO A,et al.Management of stage Ⅲ non-small-cell lung cancer:Rays of hope［J］.Explor Target Antitumor Ther,2024,5(1):85-95.
［5］ROSELL R,GONZALEZ-CAO M,ITO M,et al.The role of biomarkers in stage Ⅲ non-small cell lung cancer［J］.Expert Rev Respir Med,2023,17(6):469-480.
［6］LIU W,JIANG K,WANG J,et al.Upregulation of GNPNAT1 predicts poor prognosis and correlates with immune infiltration in lung adenocarcinoma［J］.Front Mol Biosci,2021,8(3):605754.
［7］BOEHMELT G,WAKEHAM A,ELIA A,et al.Decreased UDP-GlcNAc levels abrogate proliferation control in EMeg32-deficient cells［J］.EMBO J,2000,19(19):5092-5104.
［8］ZHAO M,LI H,MA Y,et al.Nanoparticle abraxane possesses impaired proliferation in A549 cells due to the underexpression of glucosamine 6-phosphate N-acetyltransferase 1(GNPNAT1/GNA1)［J］.Int J Nanomedicine,2017,12(3):1685-1697.
［9］KAUSHIK AK,SHOJAIE A,PANZITT K,et al.Inhibition of the hexosamine biosynthetic pathway promotes castration-resistant prostate cancer［J］.Nat Commun,2016,7(5):11612.
［10］NЙEZ-LVAREZ Y,SUELVES M.HDAC11:A multifaceted histone deacetylase with proficient fatty deacylase activity and its roles in physiological processes［J］.FEBS J,2022,289(10):2771-2792.
［11］LIU SS,WU F,JIN YM,et al.HDAC11:A rising star in epigenetics［J］.Biomed Pharmacother,2020,131(11):110607.
［12］THOLE TM,LODRINI M,FABIAN J,et al.Neuroblastoma cells depend on HDAC11 for mitotic cell cycle progression and survival［J］.Cell Death Dis,2017,8(3):e2635.
［13］BI L,REN Y,FENG M,et al.HDAC11 regulates glycolysis through the LKB1/AMPK signaling pathway to maintain hepatocellular carcinoma stemness［J］.Cancer Res,2021,81(8):2015-2028.
［14］DAI W,ZELLER C,MASROUR N,et al.Promoter CpG island methylation of genes in key cancer pathways associates with clinical outcome in high-grade serous ovarian cancer［J］.Clin Cancer Res,2013,19(20):5788-5797.
［15］HUO W,QI F,WANG K.Long non coding RNA BCYRN1 promotes prostate cancer progression via elevation of HDAC11［J］.Oncol Rep,2020,44(3):1233-1245.
［16］YANGINLAR C,LOGIE C.HDAC11 is a regulator of diverse immune functions［J］.Biochim Biophys Acta Gene Regul Mech,2018,1861(1):54-59.
［17］CHEN J,CHENG F,SAHAKIAN E,et al.HDAC11 regulates expression of C/EBPβ and immunosuppressive molecules in myeloid-derived suppressor cells［J］.J Leukoc Biol,2021,109(5):891-900.
［18］LIM W,RIDGE CA,NICHOLSON AG,et al.The 8(th) lung cancer TNM classification and clinical staging system:Review of the changes and clinical implications［J］.Quant Imaging Med Surg,2018,8(7):709-718.
［19］WANG J,LIU X,LIANG YH,et al.Acceptor substrate binding revealed by crystal structure of human glucosamine-6-phosphate N-acetyltransferase 1［J］.FEBS Lett,2008,582(20):2973-2978.
［20］AIN NU,BARONCELLI M,COSTANTINI A,et al.Novel form of rhizomelic skeletal dysplasia associated with a homozygous variant in GNPNAT1［J］.J Med Genet,2021,58(5):351-356.
［21］CHEN H,XIE C,CHEN Q,et al.HDAC11,an emerging therapeutic target for metabolic disorders［J］.Front Endocrinol(Lausanne),2022,13(10):989305.
［22］KLIESER E,URBAS R,STATTNER S,et al.Comprehensive immunohistochemical analysis of histone deacetylases in pancreatic neuroendocrine tumors:HDAC5 as a predictor of poor clinical outcome［J］.Hum Pathol,2017,65(7):41-52.

Memo

Memo:
National Natural Science Foundation of China(No.31770935);国家自然科学基金面上项目（编号：31770935）；江苏省重点研发计划专项资金项目（编号：BE2020667）
Last Update: 2024-09-30